trial

Pan European Collaboration on Antipsychotic Naïve Schizophrenia II

NCTId NCT02339844
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 130 (actual)
Sponsored by University of Copenhagen
Primary completion 2021-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
130 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2014-01
Primary completion
2021-01
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

University of CopenhagenLead Sponsor

Investigators

1
Birte Glenthøj, ProfessorStudy Director

Sites

1 total
Copenhagen, Denmark

Facts & assertions

4 sourced
Enrollment
130
Phase
PHASE4
Primary Completion Date
2021-01
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
University of Copenhagen
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Birte Glenthøj, Professor
person